Zacks has reiterated their neutral rating on shares of Boston Scientific, according to a Sleek Money report.
Zacks currently has a $16 target price on the stock. Boston Scientific traded up 0.83 percent during mid-day trading on Friday, Feb. 6, hitting $14.57. The stock had a trading volume of 1.4 million shares. The company has a 52-week low of $11.10 and a 52 week-high of $15.28, according to the report.
More articles on GI/endoscopy:
The Children's Hospital at Montefiore opens pediatric fatty liver disease clinic
Dr. Purvi Panchal joins Pennsylvania Gastroenterology Consultants
Greater Gaston Endoscopy Center officially opens in North Carolina: 5 things to know